Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance ...

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.

CHICAGO, IL, UNITED STATES, April 15, 2025 /EINPresswire.com/ -- Vitalgen BioPharma Co., Ltd. ("Vitalgen"), a pioneer in transformative gene therapy technologies, today announced its collaborative ...

VIENNA – Irish researchers presented data Saturday at the European Society of Clinical Microbiology and Infectious Diseases ...

Scientists have discovered a new immunotherapy strategy that reduces cancer recurrence in mouse experimental models. The ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective biologic developed by Takeda Pharmaceutical. The report provides ...

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic ...